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Trypanothione reductase from Trypanosomu cruzi is the most promising target molecule for the rational design of a specific drug against Chagas’ 
disease. The recombinant protein was purified in a single chromatographic step and crystallized. Two crystal forms suitable for X-ray diffraction 
analysis were obtained. Tetragonal crystals (a=b=87.4 A, ~152.3 A) were grown from 30% polyethylene glycol (average A4, = 8,000) in the presence 
of 0.2% /3-n-octylglucoside (space group either P42 with one dimer or P4222 with one monomer in the asymmetric umt). Monoclinic crystals (space 
group P2, a=l36.3 A, b=91.1 A, c=l26.0 A, /3=94”) were grown from 1.2 M sodium citrate m the presence of 2% octanoyl-jv-methyl-glucamide. 
They contain two dimers of the enzyme in the asymmetric unit: both crystal forms diffract to 3 8, resolution. 
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1. INTRODUCTION 
The thiol metabolism of nearly all organisms is based 
on the glutathione/glutathione reductase system [ 11. The 
flavoenzyme glutathione reductase keeps the [GSH]/ 
[GSSG] ratio at a high level and thus provides reducing 
equivalents for processes such as the reduction of disul- 
fides, the detoxication of peroxides and the synthesis of 
DNA precursors via the glutaredoxin system [2]. 
Trypanosomes and leishmanias, the causative agents 
of conditions such as African sleeping sickness, Chagas’ 
disease, oriental sore, Kala-azar and the Nagana cattle 
disease, show a metabolic peculiarity. These parasitic 
protozoa do not possess glutathione reductase. Rather, 
their glutathione metabolism is closely connected to 
that of polyamines, the main thiols being N’,@- 
bis(glutathionyl)spermidine (trypanothione, T(SH& [3] 
and monoglutathionylspermidine. These conjugates 
are kept in the thiol state by the flavoenzyme 
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trypanothione reductase (TR) (TS,+NADPH+H’ + 
T(SH),+NADP+). Trypanothione reductase has been 
isolated from the insect parasite Crithidiu fusciculuta [4] 
and from Trypanosoma cruzi, the causative agent of 
Chagas’ disease [5]. The trypanothione reductase genes 
of T. congofense [6] and T. cruzi [7] have been cloned 
and expressed in Escherichia coli. Although all Try- 
panosomatidae possess a trypanothione metabolism 
they are not equally sensitive to the compounds interfer- 
ing with this pathway. Difluoromethylornithine, an in- 
hibitor of spermidine synthesis which is successfully 
used as a drug against African sleeping sickness, is not 
effective against Chagas’ disease [8]. On the other hand, 
Trypanosoma cruzi is very sensitive to oxidative stress 
as indicated by the fact that the only drugs available, 
nifurtimox and benznidazole, are redox-cyclers [9]. 
Therefore trypanothione reductase is a most attractive 
target molecule for the development of a specific drug 
against Chagas’ disease. 
T. crux trypanothione reductase is structurally and 
mechanistically related to human glutathione reductase 
[5,10,11]. The crucial difference between parasite and 
host enzyme is their mutually exclusive specificity for 
the respective disulfide substrate. Comparative kinetic 
studies in solution show that a selective inhibition of T. 
cruzi trypanothione reductase should be possible 
[12,13]. For human glutathione reductase the 3-dimen- 
sional structure [ 14,151, the stereochemistry of catalysis 
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[16,17] and the binding mode of several drugs are 
known [lo]. Structural information on trypanothione 
reductase is available for the C. fasciculata enzyme 
[18,19]. This TR shows 69% sequence identity with the 
isofunctional enzyme of T. cruzi. Since even minor 
amino acid substitutions can strongly influence the 
binding of inhibitors the authentic enzyme is the candi- 
date of choice for drug design against T. cruzi. 
3. RESULTS AND DISCUSSION 
3.1. PuriJication of trypanothione reductase 
2. MATERIALS AND METHODS 
2.1. Protein pur$cation 
T. cruzi trypanothione reductase was purified from 
recombinant E. coli cells by affinity chromatography on 
2’5’ADP-Sepharose. Elution by NADPH instead of 
NADP [6] yields pure trypanothione reductase in a sin- 
gle chromatographic step. Routinely 5 to 7 mg enzyme 
were purified from a 2-liter culture. Starting out with a 
30-liter fermenter culture, the same protocol was fol- 
lowed but the dialyzed extract was chromatographed on 
2’5’ADP-Sepharose in several portions. 
Recombinant T. cruzi trypanothione reductase was produced in 
glutathione reductase-deficient E. coli SG 5 cells [20] using the over- 
producing expression vector pIBITczTR. The cells were grown and 
induced as described [6]. The enzyme was prepared according to Sul- 
livan and Walsh [7] but with several modifications. The harvested 
bactertal cells were disrupted by lysozyme digestion [21] which results 
in higher enzyme yields than sonication. 1OOg cells were suspended at 
25°C in 250 ml 50 mM potassium phosphate, 1 mM EDTA, 60 PM 
FAD, 2 mM dithiothreitol, 100pM phenyl-methane-sulfonyhluoride, 
pH 7.0, in the presence of 0.2 mg/ml ysozyme. After stirring for 5 min, 
5 ml of a 4% sodium deoxycholate solution and 2.5 mg DNase I were 
added, the suspension was stirred for 30 min at 25”C, and centrifuged. 
The supernatant was kept on ice, the cell pellet was resuspended in 
buffer, stirred for another 30 min at 25°C and cleared by centrtfuga- 
tion. The extracts were combined, and (NH&SO, was added to 70% 
saturation. After standing for 16 h at 4°C and centrifugation, the 
protein pellet was dissolved in 10 mM potassmm phosphate, 1 mM 
EDTA, pH 7.0 and ialyzed for 5 h at 25°C. The protein solution was 
then applied to a 2’5’ADPSepharose column (2 x 14 cm) previously 
equilibrated with 50 mM potassium phosphate, 1 mM EDTA, pH 7.0. 
The column was washed with 4 vol. of 50 mM potassium phosphate, 
1 mM EDTA, pH 7.0 and then equilibrated with 25 mM potassium 
phosphate, 1 mM EDTA, pH 7.0. Trypanothione reductase was eluted 
with 300 ,uM NADPH in 25 mM potassium phosphate. 1 mM EDTA, 
pH 7.0, precipitated with (NH&SO4 and stored at 4°C. 
3.2. Crystallization of the enzyme 
The crystallization behaviour of TR is influenced by 
the preparation procedure. The enzyme purified as de- 
scribed above crystallizes in the presence of 20 mM but 
not of 100 mM Tris. In contrast, 100 mM Tris was 
successfully used as a buffer to crystallize the enzyme 
prepared according to [6]. Trypanothione reductase iso- 
lated from Trypanosoma cruzi epimastigotes yielded mi- 
crocrystals using (NH&SO, as precipitant [5] whereas 
the recombinant enzyme crystallizes from citrate (so- 
dium, potassium, ammonium and lithium salts) and 
from polyethylene glycol under hanging and sitting 
drop conditions. Crystals suited for X-ray diffraction 
analysis were obtained under two different conditions. 
Monoclinic rods grew from 1.2 M sodium citrate, 20 
mM Tris, 1 mM EDTA, pH 8.0, 2% octanoyl-Wmeth- 
ylglucamide (Fig. 1). Tetragonal crystals of 200 pm x 
200 pm x 800 pm were obtained from 30% PEG-8000, 
100 mM Tris, 1 mM EDTA, pH 8.0, 0.2% /3-n-octylglu- 
coside. 
2.2. Crystallization 
The precipitate was dialysed against 20 mM Tris-HCI, 1 mM 
EDTA, pH 8.0, 500 mM sodium citrate, and adjusted to a protein 
concentration of 10-15 mg/ml. Octanoyl-N-methylglucamide was 
added to a final concentration of l-2%. 10 ~1 droplets of the protein 
solution were allowed to equilibrate by vapor diffusion with 1 ml 1.2 
M sodium citrate. Crystals grew within l-2 weeks at 20°C (Fig. 1A). 
Another crystal form of the enzyme prepared according to Sullivan 
et al. [6] was obtained from polyethylene glycol (PEG). Startmg with 
9% (w/v) PEG (average M, 8,000). 0.2% b-n-octylglucoside in 100 mM 
Tris-HCl, 1 mM EDTA, pH 8.0 in the droplet and with 30% PEG 8000 
m the reservoir, small yellow diamond-shaped crystals appeared 
within 3 days at 20°C (Fig. 1B). In some cases tetragonal yellow rods 
were obtained. All crystals of recombinant T cruzi TR grew only at 
20°C and not at 4°C. 
2.3. Crystallographic methods 
X-ray diffraction data were collected on an electromc area detector 
(SiemensMicolet, Madison, WI) at 4°C with a crystal-to-detector dis- 
tance of 13 cm. X-rays (CuK,) were generated by a GX-18 rotating 
anode (ElliotlEnraf-Nonius, Delft) and focused by Franks double 
mirror optics. The anode was operated at 35 kV and 50 mA. An 
oscillation camera (Supper, Natick, Mass.) with a vertical rotation 
axis was used to move the crystal. Camera and detector were con- 
trolled by a simplified version of a program of Blum et al. [22]. Com- 
plete sets of corrected intensity data to 3 8, resolution were extracted 
from the raw data frames by the program XDS [23,24]. Space group 
symmetry was automatically determined by an extension of the XDS 
program (Kabsch, unpublished). 
Surprisingly, the T. cruzi enzyme crystallized so far 
only in the presence of non-ionic detergents. T. congo- 
lense TR formed crystals also in the absence of deter- 
gents but addition of 0.1% /I-n-octylglucoside dramati- 
cally improved the crystals in size and shape (Krauth- 
Siegel, unpublished). 
3.3. Crystallographic analysis 
The crystals grown from polyethylene glycol were 
found to be tetragonal with unit cell dimensions 
a=b=87.4 A and ~~152.3 A, by precession photo- 
graphs. 
The autoindexing using the XDS program indicated 
that this crystal belonged to the primitive tetragonal 
lattice system, and systematic absences of reflection in- 
tensities along the c-axis allowed only P4,22 or P4, as 
possible space groups. Assuming 1 monomer or 1 dimer 
or trypanothione reductase per asymmetric unit for 
P4,22 and P4,, respectively, the specific volume I’,,, is 2.9 
A’/Da. This corresponds to a crystal solvent content of 
about 57%, which is close to the average value for crys- 
tals of a 100 kDa protein. The R-factor for the symme- 
try-related reflection intensities for both space groups 
were comparable, the merging R-factors being 13.2% 
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Fig. 1. Crystals of T. cIz(zi t~p~ot~one reductase. (A) Mon~lin~c yellow crystals (200 pm x 200~ x l,~~rn) raised in the presence of 
citrate. (8) Diamond-shaped yellow crystals (100 pm x 100 pm x 150 pm) were grown using polyethylene glycoi as a precipitant 
‘SOdiUXll 
for P4*22 (for 32,740 unique reflections) and 9.8% for 
P4, (for 22,024 unique reflections), respectively. 
The monoclinic crystals obtained from sodium citrate 
were found to have space group symmetry P2, with cell 
dimensions of a=1363 A, bz91.1 A, ~126.0 A and 
j=94”. The crystals diffract to beyond 3 A resolution 
and are stable in the X-ray beam for 5-6 days. In a total 
of 8 1,913 observations 45,259 unique reflections were 
recorded. The merging R-factor for the symmetry-re- 
lated reflection intensities was 12.9%. Assuming two 
dimers of trypanothione reductase per asymmetric unit, 
the specific volume V,,, is 3.9 A3/Da. Four dimers in the 
asymmetric unit would result in a calculated V,,, of 1.95 
A3/Da. These values are at the extremes of the range 
normally observed for protein crystals 1251. Self-rota- 
tion and cross-rotation function calculations are consis- 
tent with two dimers in the asymmetric unit. Work is in 
progress to solve this structure by molecular replace- 
ment using the data of the Crithidia fasciculata enzyme 
which were kindly made available to us by Dr. J. Kuri- 
yan [I&]. 
For functional and pharmacological purposes the so- 
dium citrate-Tris system appears to be most promising. 
Kinetic studies in the presence of 1.2 M sodium citrate, 
20 mM Tris, 1 mM EDTA, pH 8.0 yielded a K, value 
for trypanothione disulfide of 60 yM which can be re- 
garded as normal; the specific TR activity in this system 
was >25% when compared with standard assay condi- 
tions [ 121. In contrast, when e.g. 1 M ammonium sulfate 
is added to a TR assay containing 100 mM HEPES, 1 
mM EDTA, pH 7.0, the activity decreases by more than 
95%. 
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